Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Deferred Revenue (2016 - 2021)

Historic Current Deferred Revenue for Syndax Pharmaceuticals (SNDX) over the last 7 years, with Q3 2021 value amounting to $12.4 million.

  • Syndax Pharmaceuticals' Current Deferred Revenue rose 71740.28% to $12.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $12.4 million, marking a year-over-year increase of 71740.28%. This contributed to the annual value of $1.5 million for FY2020, which is 0.0% changed from last year.
  • Syndax Pharmaceuticals' Current Deferred Revenue amounted to $12.4 million in Q3 2021, which was up 71740.28% from $1.5 million recorded in Q2 2021.
  • Syndax Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $12.4 million during Q3 2021, with a 5-year trough of $1.2 million in Q1 2017.
  • For the 5-year period, Syndax Pharmaceuticals' Current Deferred Revenue averaged around $2.0 million, with its median value being $1.5 million (2018).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 356.01% in 2018, then skyrocketed by 71740.28% in 2021.
  • Syndax Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $1.6 million in 2017, then decreased by 3.56% to $1.5 million in 2018, then changed by 0.0% to $1.5 million in 2019, then changed by 0.0% to $1.5 million in 2020, then skyrocketed by 717.4% to $12.4 million in 2021.
  • Its last three reported values are $12.4 million in Q3 2021, $1.5 million for Q2 2021, and $1.5 million during Q1 2021.